Skip to main content

Table 4 Synergism between BTK inhibitors and Chemoterapy

From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

  Ibrutinib AVL-292 RN486
  CisPt Pemetr Gemcitab CisPt Pemetr Gemcitab CisPt Pemetr Gemcitab
Calu-6 0.11 ant ant 0.3 0.23 0.28 0.04 0.05 0.01
SK-Lu-1 0.09 ant ant 0.28 0.21 0.25 0.07 0.05 0.07
NCI-H1975 0.16 0.38 0.33 ant 0.51 0.52 0.08 0.05 0.02
NCI-H2228 0.22 0.41 0.41 0.47 0.43 0.47 0.06 0.06 0.03
  1. Combination Index (CI) was calculated as reported by Fransson (Fransson, A., et al. (2016) J Ovarian Res 9 [1]: 27) and detailed in material and methods
  2. 0.8 < CI < 1.2 = additive effect, CI < 0.8 = synergistic effect (CI < 0.5 = strong synergistic effect), CI > 1.2 = sub-additive effect, ant = antagonistic effect